<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-77180</identifier>
<setSpec>1695-4033</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Succinic semialdehyde dehydrogenase deficiency: Decrease in 4-OH-butyric acid levels with low doses of vigabatrin</dc:title>
<dc:description xml:lang="en">Succinic semialdehyde dehydrogenase deficiency (gamma-hydroxybutyric aciduria) is a rare neurometabolic disease caused by a deficiency in gamma-aminobutyric degradation, resulting in an increase in gamma-hydroxybutyric acid in biological fluids. The clinical spectrum is heterogeneous, including a variety of neurological manifestations and psychiatric symptoms. The treatment usually used is vigabatrin, but its clinical efficacy is under discussion. We present two affected siblings. The older brother was examined when he was 2.5 years old due to psychomotor and developmental delay, disturbances in motor coordination, axial hypotonia and language disability. His younger brother had mild axial hypotonia when 5 months old. Metabolic studies demonstrated a high plasma and urine concentration of gamma-hydroxybutyric acid. Mutation analysis of the gene ALDH5A1 confirmed the disease. After 1 year of treatment with low-doses of vigabatrin of the older patient, a decrease in gamma-hydroxybutyric acid plasma levels and a slow clinical improvement were observed (AU)</dc:description>
<dc:creator>Pérez-Cerdá, C</dc:creator>
<dc:creator>Iglesias Escalera, G</dc:creator>
<dc:creator>Ruiz Sala, P</dc:creator>
<dc:creator>Ferrer, I</dc:creator>
<dc:creator>Salomons, G. S</dc:creator>
<dc:creator>Carrasco Marina, Ll</dc:creator>
<dc:creator>Jakobs, C</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La deficiencia de succínico semialdehído deshidrogenasa o aciduria gammahidroxibutírica (GHB) es una rara enfermedad autosómica recesiva por alteración en el metabolismo del neurotransmisor inhibidor del ácido gammaaminobutírico. Debido a la deficiencia de esta enzima, se produce acúmulo del metabolito ácido GHB. El espectro clínico es heterogéneo con distintas manifestaciones neurológicas. El tratamiento más utilizado es la vigabatrina, aunque se discute su eficacia. Presentamos el caso de una familia con 2 hijos afectados. El mayor presenta retraso en la adquisición de hitos motores, marcha liberada a los 2 años, dificultad en la psicomotricidad fina, hipotonía axial, normorreflexia y retraso en el lenguaje tanto comprensivo como expresivo. Se evalúa al menor por hipotonía axial. Estudio metabólico: aumento de ácido GHB en orina y en plasma. El diagnóstico se confirma mediante el análisis de mutaciones del gen ALDH5A1. Se trata con vigabatrina en dosis bajas, lo que conduce a una disminución de los niveles de GHB en plasma en más de dos tercios y una evolución clínica favorable (AU)</dc:description>
<dc:source>An Pediatr (Barc);72(2): 128-132, feb. 2010. ilus</dc:source>
<dc:identifier>ibc-77180</dc:identifier>
<dc:title xml:lang="es">Déficit de succínico semialdehído deshidrogenasa. Disminución de los niveles de 4 OH butírico con dosis bajas de vigabatrina</dc:title>
<dc:subject>^d22935^s22045</dc:subject>
<dc:subject>^d33794^s22002</dc:subject>
<dc:subject>^d2694</dc:subject>
<dc:subject>^d2898^s22074</dc:subject>
<dc:subject>^d9313^s22012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d7983^s22012</dc:subject>
<dc:subject>^d7984^s22012</dc:subject>
<dc:subject>^d2898^s22045</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d7983^s22016</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:type>article</dc:type>
<dc:date>201002</dc:date>
</metadata>
</record>
</ibecs-document>
